Compensation analyses, regional market reports, and career-strategy articles written by our partners and senior consultants — drawn from real placement data, not third-party surveys. 38 articles covering 2021 through 2026.
Comprehensive pay data for BioPharma executives across New York — public biotech, PE-backed pharma, and pre-IPO ventures — including the equity structures that most candidates overlook.
San Francisco biotech VP R&D compensation has split into two distinct tiers. Established pharma offers one range; AI-driven drug discovery startups offer something entirely different. The numbers, and why the divergence is significant.
Texas created more senior-level life sciences positions in 2025 than every US state except California and Massachusetts. An analysis of the talent migration, compensation benchmarks, and underlying drivers.
Nearly three out of four pharma and biotech professionals who stay for a counter-offer depart within 18 months regardless. The statistics, the behavioral patterns behind them, and the uncommon scenarios where accepting actually works.
Impersonation schemes targeting life sciences job seekers have surged over the past 18 months. Twelve warning signs that distinguish a legitimate recruiter from someone after your personal data, finances, or identity.
A practical guide to exploring new opportunities without alerting your current employer — and why premium LinkedIn privacy features rarely deliver what they promise.
Citadel, Ken Griffin, Carl Icahn, Microsoft, Amazon, Apollo — Miami’s Brickell corridor now anchors a financial ecosystem that was inconceivable in 2019. The implications for senior-level professionals.
Thirty articles from 2021 through 2025 — salary guides, market analyses, and career-strategy pieces produced by the same team.
The FTC's effort to prohibit non-compete agreements triggered swift legal pushback. By late 2025, the reality for life sciences professionals bound by non-compete provisions had materially shifted from 2023 — though not in the direction most observers predicted.
By 2025, the Colorado life sciences corridor — spanning Denver, Boulder, and Fort Collins — had quietly risen to become a top-tier market for biotech and medtech talent. Its growth trajectory places it in a fundamentally different category than the "second tier" markets of recent years.
Atlanta has hosted Fortune 500 headquarters for decades — and in 2025, it is also emerging as a serious market for biotech, medtech, and digital health talent. Here is what shifted.
The 2025 Boston life sciences market is defined by a single dynamic: the GLP-1 revolution has raised the entire compensation baseline for metabolic disease leadership while other sub-sectors remain largely unchanged. Here are the verified figures.
Seattle's biotech and genomics sector has grown rapidly, anchored by the Fred Hutchinson Cancer Center, the Allen Institute, and a wave of precision medicine startups. The 2025 rebound has been genuine but inconsistent across sub-sectors.
The CSO-to-CEO transition in biopharma remains one of the most traveled paths from scientific leadership to the chief executive seat. It is also among the most difficult pivots in senior life sciences careers, with a compensation structure that catches most CSOs off guard.
Biotech board compensation is substantial, the time commitment is significant, and the legal exposure is greater than most candidates appreciate until they are already serving. Here is a framework for evaluating a biotech board seat invitation.
Equity refresh grants remain the most overlooked element of biotech compensation. A VP who secures an equity refresh policy at the point of signing will, across a four-year tenure, realize 50% to 100% more in equity value than a VP who accepts the same offer without one.
Chicago's medtech and life sciences manufacturing sector in 2024 is quieter than the coastal biotech headlines but potentially more lasting — grounded in a different structural foundation anchored by Abbott, Baxter, and a growing device startup ecosystem.
The biotech funding contraction of 2022-2023 fundamentally altered how life sciences companies approached headcount decisions. At the senior level, the consequences were precise and quantifiable — and their reverberations persist into 2024.
Philadelphia attracts less attention than Boston or San Francisco. It is not competing for headlines. The 2024 Philadelphia pharma corridor is expanding steadily — anchored by major pharma headquarters, CDMOs, and the distinctive university research ecosystem — and it merits closer examination.
The surge of fractional CMO positions in biotech between 2022 and 2024 promised senior professionals flexibility and variety. For some, it delivered on that promise. For many others, it became a lower-paying interim arrangement that postponed a stronger career move. The data is revealing.
Our placement data reveals one career stall point in pharma and biotech more frequently than any other: the Director level. Here is what causes the plateau and how to break through to VP.
In 2023, AI-driven drug discovery talent became the most sought-after specialization in life sciences. The proliferation of computational biology and ML roles is reshaping compensation benchmarks, career ladders, and how biopharma companies build R&D teams.
Professionals in traditional pharma manufacturing, legacy CROs, and declining therapeutic areas face structural contraction. Pivoting into high-growth life sciences segments — cell therapy, gene editing, digital health — requires a specific strategy that differs from conventional career-transition guidance.
Pay transparency laws are reshaping life sciences compensation. Senior professionals who understand how to interpret and leverage posted ranges in biotech and pharma hold a tangible advantage in compensation negotiations. The majority do not.
Every senior life sciences professional has heard the advice: "never take a step back." Our placement data suggests this guidance is frequently misguided — and that some of the strongest career moves involved accepting a role at a smaller biotech with a bigger impact mandate.
Choosing the right recruiter in life sciences can make or break a career move. Candidates who have had poor experiences with generalist recruiters ask us this question directly, and we believe it warrants an honest response.
The life sciences PE operating partner role occupies an unusual compensation structure — part advisory, part executive, with carried interest that may or may not materialize. In 2023, total compensation for senior life sciences PE operating partners ranged from $400K to well above $3M annually.
In 2019, most biopharma headquarters were concentrated in the Northeast. By the close of 2022, that concentration had shifted meaningfully. The migration represents billions in R&D spending and thousands of senior-level life sciences careers.
Pharma's digital transformation created unprecedented demand for tech talent in 2022. The departures from big tech into biopharma were not random. They followed a discernible pattern — and understanding it explains much about where senior digital health talent migrated.
Pharma companies assured us that remote-capable roles would not carry compensation penalties. The 2022 data told a different story — remote senior pharma professionals earned 7% less on average than comparable on-site peers at the same organizations. Here is why.
Hospital system CFOs, VP Medical Affairs, COOs of major health systems — healthcare administration compensation is substantial, structurally distinct from corporate finance, and nearly absent from public benchmarks. We are addressing that gap.
The pharma regulatory counsel market in 2022 was shaped by a single trend: life sciences companies hiring aggressively to bring regulatory and IP work in-house that was previously handled by outside counsel, at compensation levels that made the transition compelling.
The biotech funding winter that began in late 2021 reshaped the entire life sciences talent landscape. The sustained downturn offered an unexpected case study in how institutional knowledge disperses — and how the senior talent market absorbs prolonged capital constraints.
Conventional wisdom in life sciences holds that senior careers move upward. The actual data indicates that the most valuable moves often go laterally — into a different therapeutic area, a new modality, or a smaller biotech with a broader mandate.
Most biotech candidates fixate on grant size. The variables that truly determine realized equity value — vesting schedule, refresh policy, acceleration clauses, and tax treatment — are nearly always negotiable and nearly always overlooked.
Life sciences leadership turnover reached unprecedented levels in 2021. Among senior executives and VP-level professionals in pharma and biotech, the mechanics of the talent market are fundamentally different from what the headlines portrayed.
The Chief Medical Officer role in biopharma has evolved from a regulatory figurehead to a strategic linchpin. Its compensation reflects the urgency organizations attach to clinical development leadership — and the scarcity of candidates who combine scientific depth with commercial acumen.
Kendall Square now has more biotech R&D spending per square mile than anywhere else on earth. The labor market for senior science and clinical leadership reflects that concentration — and behaves by different rules than any other senior US market.